SEC Form 4 · accession 0000897069-26-001602
Processa Pharmaceuticals, Inc. · PCSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George K Ng
Officer — Chief Executive Officer · Director
Period of report
Aug 8, 2026
Accepted (ET)
Aug 11, 2026 · 4:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001533743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 8, 2026 | M | 1,600 | — | A | 17,092 | D | |
| Common Stock | holding | — | — | — | 3,488 | I | George Ng IRRA FOB George Ng | |
| Common Stock | holding | — | — | — | 800 | I | Ng Cha Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted StockF3,F1 | $0.00 | Aug 8, 2026 | M | 1,600 | D | — | — | Common Stock | 1,600 | 19,624 | D |
| Stock Options (Right to Buy)F3,F2 | $4.96 | holding | — | — | — | — | — | Common Stock | 30,720 | 30,720 | D |
Explanation of responses
- F1Distribution of time-based service award.
- F2Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.